CANSINOBIO(SH:688185) Sou Hu Cai Jing·2026-02-21 02:12Core Viewpoint - The article highlights the significant decline in the stock prices of high-priced new shares in the A-share market, with a staggering 70% of the top ten highest-priced new stocks falling below their issuance prices, leading to substantial losses for investors [1][4]. Group 1: Stock Performance - Seven out of the ten highest-priced new stocks have dropped below their issuance prices, with a breakage rate of 70% [1][4]. - The stock with the most severe decline, 康希诺 (688185), plummeted from a peak of 797.2 yuan to 63.9 yuan, representing a drop of over 93% [2][3]. - Other high-priced stocks like 禾迈股份 (688032) and 万润新能 have also seen significant declines, with their prices falling below their issuance prices, resulting in substantial losses for investors [3][4]. Group 2: Reasons for Decline - The decline in high-priced new stocks can be attributed to three main factors: excessively high issuance prices, a decline in industry popularity, and poor performance post-listing [4][5]. - Many of these stocks had issuance price-to-earnings ratios far exceeding industry averages, leading to overvaluation at the time of listing [4]. - The fading popularity of sectors such as vaccines and solar energy has resulted in companies struggling to maintain high valuations due to lack of performance support [4][5]. Group 3: Investor Sentiment and Market Trends - Investors have expressed frustration, noting that the previous trend of guaranteed profits from new stock subscriptions has shifted to a more lottery-like experience, where risks are significantly higher [4][5]. - The article emphasizes the importance of avoiding blind speculation and highlights the need for investors to focus on companies with solid fundamentals and reasonable valuations [5][7]. - The collective decline of high-priced new stocks serves as a warning to investors to avoid blindly chasing high prices and to adopt a more rational investment approach [7].